Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

523
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
523
  1. Home
  3. Association Of Pretreatment Neutrophil-to-lymphocyte Ratio With Clinical Outcomes In Cancer Immunotherapy: An Evidence Synthesis From 30 Meta-analyses.
  1. Home
  3. Association Of Pretreatment Neutrophil-to-lymphocyte Ratio With Clinical Outcomes In Cancer Immunotherapy: An Evidence Synthesis From 30 Meta-analyses.

Related Experiment Video

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.3K

Association of pretreatment neutrophil-to-lymphocyte ratio with clinical outcomes in cancer immunotherapy: An

Haoyu Wang1, Ruiyuan Yang1, Dan Liu1

  • 1Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China.

International Immunopharmacology
|April 5, 2024

View abstract on PubMed

Summary
This summary is machine-generated.
Keywords:
CancerImmune checkpoint inhibitorsImmunotherapyNeutrophil-to-lymphocyte ratioUmbrella review

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.1K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K

Related Experiment Videos

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.3K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.1K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K

Elevated pretreatment Neutrophil-to-lymphocyte ratio (NLR) is linked to poorer cancer immunotherapy outcomes. This biomarker shows potential for patient selection and outcome prediction, but requires further validation.

Area of Science:

  • Oncology
  • Immunology
  • Biomarker Research

Background:

  • The Neutrophil-to-lymphocyte ratio (NLR) is a potential predictor of cancer immunotherapy success.
  • Limited validation exists for pretreatment NLR's association with immunotherapy outcomes.
  • An umbrella review was performed to assess this association and its evidence strength.

Purpose of the Study:

  • To comprehensively evaluate the association between pretreatment NLR and cancer immunotherapy outcomes.
  • To assess the credibility and strength of evidence linking NLR to immunotherapy results.

Main Methods:

  • Systematic search of electronic databases (PubMed, Web of Science, Embase, Scopus, Cochrane).
  • Inclusion of systematic reviews and meta-analyses.
  • Quality assessment and evidence grading using AMSTAR, GRADE, PRISMA, and PRIOR guidelines.

Main Results:

  • Thirty meta-analyses were included in the review.
  • Eighty percent (24 associations) showed statistically significant results.
  • Highly suggestive or convincing evidence linked pretreatment NLR to poor prognosis in renal cell carcinoma, hepatocellular carcinoma, melanoma, and non-small cell lung cancer.

Conclusions:

  • Elevated pretreatment NLR correlates with adverse outcomes in cancer immunotherapy.
  • Pretreatment NLR may serve as a biomarker for identifying suitable patient populations and predicting clinical outcomes.
  • Prospective cohort studies are needed for further validation.